Treatment of mycosis fungoides with OK-432.
Up to the present no other therapeutic means besides local X-ray or beta-ray irradiation and anticancer drugs for the treatment of patients with mycosis fungoides, especially when the condition has progressed to secondary involvement of the lymph nodes, has been found. A recent clinical trial of OK-432 injected locally into cutaneous tumors of a patient with this disease resulted in a conspicuous contraction not only of the tumors injected but of other tumors as well along with significant regression of lymphadenomas. No serious adverse reaction was observed other than low-grade fever and heavy-headedness. These results suggest host-mediated and direct antitumor effects of OK-432 as the possible underlying mechanisms. The efficacy of OK-432 in reducing the size of the tumors without causing any serious adverse effects indicate the potential usefulness of this drug for the treatment of mycosis fungoides.
Department of Dermatology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showaku, Nagoya 466, Japan.
Y
Y
Sawada
M
M
Ohashi
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D015552:Injections, Intralesional; D007564:Japan; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology*; D009367:Neoplasm Staging; D010844:Picibanil / Q000627:therapeutic use*; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010844:Picibanil